Search

Displaying results 2281 - 2290 of 7452 in total
  1. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]

  2. Drug

    Polidocanol

    go.drugbank.com/drugs/DB06811
    ApprovedInvestigational

    The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.

    Categories: Sclerosing Agents for Local Injection, Compounds used in a research, industrial, or household setting
  3. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

    Categories: Experimental Unapproved Treatments for COVID-19
  4. Drug

    AUTO3

    go.drugbank.com/drugs/DB17364
    Investigational

    AUTO3 is bicistronic chimeric antigen receptor T-cell therapy investigated for acute lymphoblastic leukemia (ALL).

  5. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63814,L63930] Reduced gadolinium exposure is important for patients requiring repeated lifetime imaging - e.g. for multiple sclerosis, spinal conditions, or cancer surveillance - given clinical guidance … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity

  6. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.

  7. Drug

    Flupentixol

    go.drugbank.com/drugs/DB00875
    ApprovedInvestigationalWithdrawn

    It is approved for use in Canada and other countries around the world, but not in the US. … It is used for the management of chronic schizophrenia in patients whose main manifestations do not include excitement, agitation or hyperactivity.

  8. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    It is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally given as oral tablets in divided doses, three or four times a day. … Amifampridine is the nonimmune treatment options for LEMS.

  10. Drug

    Brexpiprazole

    go.drugbank.com/drugs/DB09128
    ApprovedInvestigational

    It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. … [L46417] Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors.

    Categories: Antidepressive Agents Indicated for Depression